Editas Medicine, Inc.
(NASDAQ : EDIT)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Loading EDIT News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.18%165.741.2%$778.89m
INCYIncyte Corporation
0.48%139.641.7%$592.23m
GILDGilead Sciences, Inc.
0.03%67.511.0%$577.68m
CELGCelgene Corporation
0.13%123.381.0%$494.27m
BIIBBiogen Inc.
-0.21%274.821.3%$452.48m
REGNRegeneron Pharmaceuticals, Inc.
2.19%373.002.1%$320.06m
KITEKite Pharma, Inc.
3.14%76.8418.8%$224.79m
ALXNAlexion Pharmaceuticals, Inc.
-0.83%119.261.6%$202.56m
TSROTESARO, Inc.
4.15%160.0016.1%$189.31m
ESPREsperion Therapeutics, Inc.
-3.61%38.9418.7%$173.60m
ILMNIllumina, Inc.
1.72%170.583.7%$172.89m
AUPHAurinia Pharmaceuticals Inc.
-4.41%8.026.3%$150.20m
CLVSClovis Oncology, Inc.
2.61%70.3217.5%$142.57m
VRTXVertex Pharmaceuticals Incorporated
1.04%89.982.2%$135.11m
EXELExelixis, Inc.
2.95%20.917.0%$105.88m

Company Profile

Editas Medicine, Inc. engages in the development and commercialization of genome editting technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR); and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu on September 3, 2013 and is headquartered in Cambridge, MA.^ ^ ^